[Omalizumab for the treatment of food allergies in adults].

Abstract

The growing prevalence of food allergies has social and economic impact. Therapeutic options are limited, with food avoidance remaining the main approach. Omalizumab, an anti-IgE monoclonal antibody approved for asthma, nasal polyposis, and chronic spontaneous urticaria, shows promise in treating food allergies. However, this costly treatment requires ongoing administration with an undefined duration and does not allow for the cessation of food avoidance. Further research is needed to define its indications and assess its long-term impact.